ARGX Stock - argenx SE
Unlock GoAI Insights for ARGX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.19B | $1.23B | $410.75M | $497.28M | $41.24M |
| Gross Profit | $1.96B | $1.11B | $381.31M | $497.28M | $41.24M |
| Gross Margin | 89.6% | 90.4% | 92.8% | 100.0% | 100.0% |
| Operating Income | $-21,654,000 | $-425,049,000 | $-720,341,000 | $-348,746,000 | $-477,617,000 |
| Net Income | $833.04M | $-295,053,000 | $-709,594,000 | $-407,626,000 | $-608,455,000 |
| Net Margin | 38.0% | -24.1% | -172.8% | -82.0% | -1475.3% |
| EPS | $13.92 | $-5.16 | $-13.05 | $-7.99 | $-13.40 |
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Visit WebsiteEarnings History & Surprises
ARGXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | $5.92 | — | — | — |
Q4 2025 | Oct 30, 2025 | $4.37 | $5.18 | +18.5% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $0.98 | $2.58 | +163.3% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | — | $2.83 | — | — |
Q4 2024 | Oct 31, 2024 | $0.10 | $1.39 | +1290.0% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.71 | $-1.04 | -46.5% | ✗ MISS |
Q1 2024 | Mar 31, 2024 | — | $-1.12 | — | — |
Q4 2023 | Oct 31, 2023 | $-1.48 | $-1.25 | +15.5% | ✓ BEAT |
Q3 2023 | Sep 30, 2023 | — | $-1.32 | — | — |
Q2 2023 | Jun 21, 2023 | — | $0.89 | — | — |
Q2 2023 | May 4, 2023 | $-2.34 | $-0.52 | +77.8% | ✓ BEAT |
Q4 2021 | Oct 28, 2021 | $-4.48 | $-4.40 | +1.8% | ✓ BEAT |
Q2 2021 | May 14, 2021 | $-3.14 | $-0.81 | +74.2% | ✓ BEAT |
Q4 2020 | Oct 22, 2020 | $-2.80 | $-3.96 | -41.4% | ✗ MISS |
Q2 2020 | May 14, 2020 | $-1.88 | $-2.06 | -9.6% | ✗ MISS |
Q4 2019 | Oct 24, 2019 | $-1.17 | $-0.66 | +43.6% | ✓ BEAT |
Q2 2019 | May 9, 2019 | $-0.74 | $0.17 | +123.0% | ✓ BEAT |
Q4 2018 | Oct 25, 2018 | $-0.68 | $-0.51 | +25.0% | ✓ BEAT |
Q2 2018 | May 9, 2018 | $-0.38 | $-0.55 | -44.7% | ✗ MISS |
Q4 2017 | Oct 26, 2017 | $-0.34 | $-0.41 | -20.6% | ✗ MISS |
Latest News
Frequently Asked Questions about ARGX
What is ARGX's current stock price?
What is the analyst price target for ARGX?
What sector is argenx SE in?
What is ARGX's market cap?
Does ARGX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ARGX for comparison